牛牛AI助理已提取核心訊息
On January 12, 2024, In8bio, Inc., a Delaware-based clinical-stage biopharmaceutical company, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC). The filing pertains to the proposed sale of up to 42,703,475 shares of common stock by selling stockholders. These shares include those issued in a private placement on December 13, 2023, and shares pursuant to an Investors' Rights Agreement dated May 7, 2018. The company will not sell any shares nor receive proceeds from the selling stockholders' sales, but will receive proceeds from any cash exercises of warrants. The shares may be sold from time to time after the registration statement becomes effective, at market prices or negotiated prices through various methods including block trades and underwriters. The company's common stock is listed on the Nasdaq Global Market under the symbol 'INAB'.
On January 12, 2024, In8bio, Inc., a Delaware-based clinical-stage biopharmaceutical company, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC). The filing pertains to the proposed sale of up to 42,703,475 shares of common stock by selling stockholders. These shares include those issued in a private placement on December 13, 2023, and shares pursuant to an Investors' Rights Agreement dated May 7, 2018. The company will not sell any shares nor receive proceeds from the selling stockholders' sales, but will receive proceeds from any cash exercises of warrants. The shares may be sold from time to time after the registration statement becomes effective, at market prices or negotiated prices through various methods including block trades and underwriters. The company's common stock is listed on the Nasdaq Global Market under the symbol 'INAB'.
2024年1月12日，總部位於特拉華州的臨床階段生物製藥公司in8Bio, Inc. 向美國證券交易委員會（SEC）提交了S-3表格註冊聲明。該文件涉及出售股東擬出售多達42,703,475股普通股。這些股票包括2023年12月13日私募發行的股票，以及根據2018年5月7日投資者權利協議發行的股票。該公司不會出售任何股票，也不會從出售股東的銷售中獲得收益，但將從認股權證的任何現金行使中獲得收益。註冊聲明生效後，可以通過包括大宗交易和承銷商在內的各種方法，以市場價格或協議價格不時出售股票。該公司的普通股在納斯達克全球市場上市，股票代碼爲 “INAB”。
2024年1月12日，總部位於特拉華州的臨床階段生物製藥公司in8Bio, Inc. 向美國證券交易委員會（SEC）提交了S-3表格註冊聲明。該文件涉及出售股東擬出售多達42,703,475股普通股。這些股票包括2023年12月13日私募發行的股票，以及根據2018年5月7日投資者權利協議發行的股票。該公司不會出售任何股票，也不會從出售股東的銷售中獲得收益，但將從認股權證的任何現金行使中獲得收益。註冊聲明生效後，可以通過包括大宗交易和承銷商在內的各種方法，以市場價格或協議價格不時出售股票。該公司的普通股在納斯達克全球市場上市，股票代碼爲 “INAB”。
有用
沒用